Vikram Purohit
Stock Analyst at Morgan Stanley
(1.70)
# 3,331
Out of 5,174 analysts
162
Total ratings
27.69%
Success rate
-9.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Overweight | $11 → $18 | $5.22 | +244.83% | 3 | Feb 18, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $92 → $94 | $90.62 | +3.73% | 26 | Jan 6, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $21.06 | +61.44% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $62.04 | +27.34% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $3.01 | +95.68% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $3.17 | +57.73% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $215.54 | +15.99% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $158.75 | +19.69% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.80 | +87.50% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $25.81 | +20.11% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $110.17 | -85.48% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $21.83 | -54.19% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $7.81 | +437.77% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $74.42 | -44.91% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $8.47 | +372.26% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $1.79 | +626.26% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $11.57 | +228.44% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $6.25 | +220.00% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $14.90 | -32.89% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.03 | +2,035.92% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $19.63 | +1.88% | 2 | Aug 5, 2020 |
COMPASS Pathways
Feb 18, 2026
Maintains: Overweight
Price Target: $11 → $18
Current: $5.22
Upside: +244.83%
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92 → $94
Current: $90.62
Upside: +3.73%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $21.06
Upside: +61.44%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $62.04
Upside: +27.34%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $3.01
Upside: +95.68%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $3.17
Upside: +57.73%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $215.54
Upside: +15.99%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $158.75
Upside: +19.69%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.80
Upside: +87.50%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $25.81
Upside: +20.11%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $110.17
Upside: -85.48%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $21.83
Upside: -54.19%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $7.81
Upside: +437.77%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $74.42
Upside: -44.91%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $8.47
Upside: +372.26%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $1.79
Upside: +626.26%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $11.57
Upside: +228.44%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $6.25
Upside: +220.00%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $14.90
Upside: -32.89%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.03
Upside: +2,035.92%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $19.63
Upside: +1.88%